Disabled Patients Skew Medicare Rx Benefit Design
Pharmaceutical Executive
If policy makers crafting a Medicare pharmacy benefit are worried about heavy prescription spending by seniors, they should take a closer look at medication use by the five million disabled beneficiaries in the program of 40 million patients.
If policy makers crafting a Medicare pharmacy benefit are worried about heavy prescription spending by seniors, they should take a closer look at medication use by the five million disabled beneficiaries in the program of 40 million patients. Medicare provides healthcare coverage for individuals under 65 who are totally and permanently disabled. Many qualify for Medicaid pharmacy benefits, but their low incomes make paying for prescription medicines particularly burdensome, according to a report on "Medicare's Disabled Beneficiaries: The Forgotten Population in the Debate Over Drug Benefits" from the Commonwealth Fund and the Henry J. Kaiser Family Foundation. That population fills more prescriptions and spends more on medicines each year than the elderly. (See "The Other Medicare Patients.")
The Other Medicare Patients
Moreover, the report points out, disabled Medicare beneficiaries use a different mix of pharmaceuticals than seniors do. Most notable is the heavy use of psychotherapeutics and analgesics -both low on the list of drugs commonly used by Medicare patients. (See "One Program, Two Lists.")
One Program, Two Lists
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
